1. Investigation of a Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) Variant Outbreak Among Residents of a Skilled Nursing Facility and Vaccine Effectiveness Analysis: Maricopa County, Arizona, June–July 2021.
- Author
-
Dale, Ariella P, Almendares, Olivia, Howard, Brandon J, Burnett, Eleanor, Prasai, Siru, Arons, Melissa, Collins, Jennifer, Duffy, Nadezdha, Pandit, Urvashi, Brady, Shane, White, Jessica R, Garrett, Brenna, Kirking, Hannah L, Sunenshine, Rebecca, Tate, Jacqueline E, and Scott, Sarah E
- Subjects
- *
IMMUNIZATION , *VACCINE effectiveness , *COVID-19 testing , *IMMUNOCOMPROMISED patients , *HOSPITAL care , *DESCRIPTIVE statistics , *COVID-19 vaccines , *NURSING care facilities , *REHABILITATION centers , *ELECTRONIC health records , *GENETIC mutation , *CONFIDENCE intervals , *COVID-19 pandemic , *PROPORTIONAL hazards models , *COVID-19 , *EVALUATION - Abstract
Background Short-term rehabilitation units present unique infection control challenges because of high turnover and medically complex residents. In June 2021, the Maricopa County Department of Public Health was notified of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta outbreak in a skilled nursing facility short-term rehabilitation unit. We describe the outbreak and assess vaccine effectiveness (VE). Methods Facility electronic medical records were reviewed for residents who spent > 1 night on the affected unit between June 10 and July 23, 2021, to collect demographics, SARS-CoV-2 test results, underlying medical conditions, vaccination status, and clinical outcomes. Coronavirus disease 2019 VE estimates using Cox proportional hazards models were calculated. Results Forty (37%) of 109 short-stay rehabilitation unit residents who met inclusion criteria tested positive for SARS-CoV-2. SARS-CoV-2-positive case-patients were mostly male (58%) and White (78%) with a median age of 65 (range, 27-92) years; 11 (27%) were immunocompromised. Of residents, 39% (10 cases, 32 noncases) received 2 doses and 9% (4 cases, 6 noncases) received 1 dose of messenger RNA (mRNA) vaccine. Among nonimmunocompromised residents, adjusted 2-dose primary-series mRNA VE against symptomatic infection was 80% (95% confidence interval, 15-95). More cases were hospitalized (33%) or died (38%) than noncases (10% hospitalized; 16% died). Conclusions In this large SARS-CoV-2 Delta outbreak in a high-turnover short-term rehabilitation unit, a low vaccination rate and medically complex resident population were noted alongside severe outcomes. VE of 2-dose primary-series mRNA vaccine against symptomatic infection was the highest in nonimmunocompromised residents. Health departments can use vaccine coverage data to prioritize facilities for assistance in preventing outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF